FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis
Hope for Children with Rare Inflammatory Disease: New Treatment Receives FDA Designation
A breakthrough treatment for a debilitating childhood illness has received a significant boost from the FDA, offering renewed hope for families affected by systemic juvenile idiopathic arthritis (sJIA).
PIF Partners recently announced that its investigational therapeutic, 101-PGC-005 (‘005), has been granted Rare Pediatric Disease Designation by the FDA.This designation is reserved for drugs targeting serious or life-threatening diseases primarily affecting children under 18.
sJIA is a rare and severe autoinflammatory disease that strikes children under 16, causing a range of debilitating symptoms. These can include high fevers, painful joint inflammation, rashes, and even inflammation of the heart and lung linings.
“We are thrilled the FDA has recognized the potential of ‘005 to address the significant unmet medical needs of children suffering from sJIA,” said Alec Goldberg, CEO of PIF Partners.
‘005 is a Type IA prodrug of dexamethasone that specifically targets CD206+ macrophages, immune cells involved in inflammation. This targeted approach aims to enhance efficacy while minimizing side effects.
“By targeting activated macrophages with the most powerful anti-inflammatory compounds,we enhance efficacy and reduce toxicity,” Goldberg explained. “Critically, we have demonstrated no suppression of the HPA system, thus supplementing rather than replacing the natural anti-inflammatory response.”
The designation is a major milestone for PIF partners, paving the way for expedited development and review of ‘005. The company is currently conducting Phase 3 clinical trials in India to evaluate the drug’s effectiveness in treating acute respiratory distress syndrome induced by COVID-19.
This news comes on the heels of another potential breakthrough for children with inflammatory conditions. Johnson & Johnson recently submitted applications to the FDA for guselkumab (Tremfya) to treat both juvenile psoriatic arthritis (jPsA) and moderate-to-severe plaque psoriasis in children.
The FDA’s focus on rare pediatric diseases and the ongoing research into innovative treatments like ‘005 and guselkumab offer a glimmer of hope for children and families facing these challenging conditions.
Hope for Children with Rare Inflammatory Disease: New Treatment Receives FDA Designation
[City, State] – A breakthrough treatment for a debilitating childhood illness has received a significant boost from the FDA, offering renewed hope for families affected by systemic juvenile idiopathic arthritis (sJIA).
PIF Partners recently announced that its investigational therapeutic, 101-PGC-005 (‘005), has been granted Rare Pediatric Disease Designation by the FDA. this designation is reserved for drugs targeting serious or life-threatening diseases primarily affecting children under 18.
sJIA is a rare and severe autoinflammatory disease that strikes children under 16, causing a range of debilitating symptoms. These can include high fevers, painful joint inflammation, rashes, and even inflammation of the heart and lung linings.
“We are thrilled the FDA has recognized the potential of ‘005 to address the significant unmet medical needs of children suffering from sJIA,” saeid alec Goldberg,CEO of PIF Partners.
‘005 is a Type IA prodrug of dexamethasone that specifically targets CD206+ macrophages, immune cells involved in inflammation. This targeted approach aims to enhance efficacy while minimizing side effects.
“By targeting activated macrophages with the most powerful anti-inflammatory compounds,we enhance efficacy and reduce toxicity,” Goldberg explained. “Critically, we have demonstrated no suppression of the HPA system, thus supplementing rather than replacing the natural anti-inflammatory response.”
The designation is a major milestone for PIF partners, paving the way for expedited advancement and review of ’005. The company is currently conducting Phase 3 clinical trials in India to evaluate the drug’s effectiveness in treating acute respiratory distress syndrome induced by COVID-19.
This news comes on the heels of another potential breakthrough for children with inflammatory conditions.Johnson & Johnson recently submitted applications to the FDA for guselkumab (Tremfya) to treat both juvenile psoriatic arthritis (jPsA) and moderate-to-severe plaque psoriasis in children.
the FDA’s focus on rare pediatric diseases and the ongoing research into innovative treatments like ‘005 and guselkumab offer a glimmer of hope for children and families facing these challenging conditions.